Li Zeng

CEO

Jing Medicine

Short Biography

Dr. Li ZENG joined Jing Medicine as Chief Executive Officer in November 2021, bringing with him a wealth of R&D and business operation experience in pharmaceutical industry with a career spanning over 18 years. he has held drug R&D, portfolio and project management positions of increasing responsibilities in multinational companies such as Novartis and Eli Lilly as well as in traditional local pharma and biotech firms such as Luoxin Pharmaceutical, 4B Technologies and Harbour Biomed.  
Dr. Zeng received his bachelor’s degree in chemistry from Peking University and Ph.D. in Organic Chemistry from Stanford University. He conducted his postdoctoral research training in Chemical Biology at University of California, Berkeley.

Presentation Topic:  Non-Small Cell Lung Cancer (NSCLC) Treatment and PROTAC as a New Targeted Therapy Strategy
Lung cancer is a leading cause of cancer-related deaths, and non-small cell lung cancer (NSCLC) makes up 85% of all cases. A subset of NSCLC patients harboring epidermal growth factor receptor (EGFR) mutations can be treated with EGFR targeted kinase inhibitors, but resistance will ultimately occur and new strategies that overcome drug resistance are urgently needed. In addition to immunotherapy, bispecific antibody, and antibody-drug conjugate, proteolysis-targeting chimera (PROTAC) has emerged as a paradigm-shifting approach to address the resistance mutation issue. In this presentation, the discovery and development of a potent, selective and orally bioavailable EGFR-PROTAC molecule HJ-004 will be presented and discussed. This approach can be extended to other actionable mutations in NSCLC such as KRAS, ALK, ROS1, and BRAF in order to improve patient treatment outcomes.